PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying immunotherapy as a possible treatment for metastatic Triple
Negative Breast Cancer (TNBC) in participants who are HLA-A2+.
The drugs involved in this study are:
- PVX-410
- Pembrolizumab
- Hiltonol
- Montanide